Overview

Repinotan in Patients With Acute Ischemic Stroke

Status:
Completed

Trial end date:
2004-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.

Phase:

Phase 2

Details

Lead Sponsor:

Bayer

Treatments:

Repinotan hydrochloride